TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Blind Pharmacodynamic Study to Assess the Phosphate Binding Characteristics of K2CG Chewing Gum
Brief Summary: The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG chewing gum.


Options:
A: Arm Label: Subjects with normal kidney function; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Arm Label: CKD late Stage 3 and Stage 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Intervention Type: DIETARY_SUPPLEMENT; Name: High calcium diet 2000 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function | Intervention Type: DIETARY_SUPPLEMENT; Name: Low calcium diet, 800 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function
B: Arm Label: K2CG chewing gum (20 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (20mg chitosan) | Arm Label: K2CG chewing gum (60 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (60mg chitosan) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: K2CG chewing gum (20mg chitosan); Assigned to Arm(s): K2CG chewing gum (20 mg chitosan) | Intervention Type: OTHER; Name: K2CG chewing gum (60mg chitosan); Assigned to Arm(s): K2CG chewing gum (60 mg chitosan)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Chewing Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial
Brief Summary: Oxygen administration is a common practice in intensive care units, although concern is growing about oxygen toxicity. The aim of the study is to access whether a rigorous maintenance of a state of normal oxygenation in critically ill patients could obtain better outcomes, such as mortality, infections and organ failures, in comparison to conventional oxygen therapy practice.


Options:
A: Arm Label: Low oxygenation target; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: High oxygenation target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Low oxygenation target | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): High oxygenation target
B: Arm Label: Liberal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liberal Oxygen | Arm Label: Titrated oxygen; Type: EXPERIMENTAL; Interventions: Drug: Titrated Oxygen | Intervention Type: DRUG; Name: Titrated Oxygen; Assigned to Arm(s): Titrated oxygen | Intervention Type: DRUG; Name: Liberal Oxygen; Assigned to Arm(s): Liberal oxygen
C: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen
D: Arm Label: Oxygenation, rigorous normal; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: Oxygen, free conventional; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygenation, rigorous normal

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care
Brief Summary: The aim of PR1MaC is to establish a clinical intervention that will adapt and permanently integrate rehabilitation services into primary care settings, which would be the reference point in the health care system for people with Chronic diseases (CD). More specifically, the intervention will aim to: (1) clinically operationalize the mechanisms and tools necessary for delivery of integrated CD services, promoting continuity of care in response to the needs expressed by stakeholders; (2) implement and deploy rehabilitation services adapted to the realities of various clinical primary care settings and develop tools to ensure the sustainability of interventions beyond the rehabilitation period; and (3) support clinical primary care teams in the acquisition and maintenance of evidence-based practices for the targeted CDs.


Options:
A: Arm Label: Usual information policy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Antibiotic therapy guidelines; Type: OTHER; Interventions: Other: Mailing of antibiotic therapy guidelines to the sentinel physicians | Intervention Type: OTHER; Name: Mailing of antibiotic therapy guidelines to the sentinel physicians; Assigned to Arm(s): Antibiotic therapy guidelines
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Active implementation of a guideline for chronic disease | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: External control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active implementation of a guideline for chronic disease; Assigned to Arm(s): Intervention
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care
Brief Summary: The aim of PR1MaC is to establish a clinical intervention that will adapt and permanently integrate rehabilitation services into primary care settings, which would be the reference point in the health care system for people with Chronic diseases (CD). More specifically, the intervention will aim to: (1) clinically operationalize the mechanisms and tools necessary for delivery of integrated CD services, promoting continuity of care in response to the needs expressed by stakeholders; (2) implement and deploy rehabilitation services adapted to the realities of various clinical primary care settings and develop tools to ensure the sustainability of interventions beyond the rehabilitation period; and (3) support clinical primary care teams in the acquisition and maintenance of evidence-based practices for the targeted CDs.


Options:
A: Arm Label: QualiCCare education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: active comparator, QualiCCare education | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: active comparator, QualiCCare education; Assigned to Arm(s): QualiCCare education
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ususal care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: RT management | Intervention Type: OTHER; Name: RT management; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Ususal care; Assigned to Arm(s): Control
D: Arm Label: traditional chinese medicine; Type: EXPERIMENTAL; Interventions: Drug: Traditional Chinese Medicine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo chinese medicine | Intervention Type: DRUG; Name: Traditional Chinese Medicine; Assigned to Arm(s): traditional chinese medicine | Intervention Type: DRUG; Name: placebo chinese medicine; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care
Brief Summary: The aim of PR1MaC is to establish a clinical intervention that will adapt and permanently integrate rehabilitation services into primary care settings, which would be the reference point in the health care system for people with Chronic diseases (CD). More specifically, the intervention will aim to: (1) clinically operationalize the mechanisms and tools necessary for delivery of integrated CD services, promoting continuity of care in response to the needs expressed by stakeholders; (2) implement and deploy rehabilitation services adapted to the realities of various clinical primary care settings and develop tools to ensure the sustainability of interventions beyond the rehabilitation period; and (3) support clinical primary care teams in the acquisition and maintenance of evidence-based practices for the targeted CDs.


Options:
A: Arm Label: PREPARE; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE website | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advance directive | Intervention Type: BEHAVIORAL; Name: PREPARE website; Assigned to Arm(s): PREPARE | Intervention Type: BEHAVIORAL; Name: Advance directive; Assigned to Arm(s): CONTROL
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
C: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care
Brief Summary: The aim of PR1MaC is to establish a clinical intervention that will adapt and permanently integrate rehabilitation services into primary care settings, which would be the reference point in the health care system for people with Chronic diseases (CD). More specifically, the intervention will aim to: (1) clinically operationalize the mechanisms and tools necessary for delivery of integrated CD services, promoting continuity of care in response to the needs expressed by stakeholders; (2) implement and deploy rehabilitation services adapted to the realities of various clinical primary care settings and develop tools to ensure the sustainability of interventions beyond the rehabilitation period; and (3) support clinical primary care teams in the acquisition and maintenance of evidence-based practices for the targeted CDs.


Options:
A: Arm Label: Pulmonary Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Intervention; Assigned to Arm(s): Pulmonary Rehabilitation Group
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
C: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Lidocaine for Effective Pain Relief After Posterior Lumbar Spinal Fusion: a Prospective, Randomized, Double-blind, Placebo-controlled Study
Brief Summary: This prospective randomized study aims to evaluate the effectiveness of intravenous lidocaine injection on the relief of pain in patients undergoing 1-level posterior lumbar fusion.

A total of 54 patients will be randomized into one of two groups (group C or group I) based on Excel number generation.

Patients in group C will receive received normal saline intravenous injection, and patients in group I will receive an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.

Visual analogue scale pain scores, fentanyl consumption and the frequency at which patients pushed the button (FPB) of a patient-controlled analgesia system will be recorded at 4, 12, 24, 48 hours postoperatively.


Options:
A: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Placebo control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Placebo control group
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: lidocaine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupivacaine with hydromorphone | Intervention Type: DRUG; Name: bupivacaine with hydromorphone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 2
C: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine Intravenous Infusion | Intervention Type: DRUG; Name: Lidocaine Intravenous Infusion; Assigned to Arm(s): Lidocaine
D: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury. A Randomised Study (FLORALI Study)
Brief Summary: The aim of the study is to compare, in patients with acute respiratory failure/acute lung injury the efficacy of three different methods of oxygenation to prevent endotracheal intubation :

1. conventional oxygen therapy (O2 conventional)
2. high flow nasal oxygen therapy (O2-HFN)
3. association of high flow nasal oxygen therapy with non invasive positive pressure ventilation (O2-HFN/NPPV).


Options:
A: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow
B: Arm Label: O2 conventional : standard low flow therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: O2 conventional | Arm Label: O2-HNF : high flow nasal oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: O2-HFN : high flow nasal oxygen therapy | Arm Label: O2-HFN/NPPV; Type: EXPERIMENTAL; Interventions: Device: O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation | Intervention Type: OTHER; Name: O2 conventional; Assigned to Arm(s): O2 conventional : standard low flow therapy | Intervention Type: DEVICE; Name: O2-HFN : high flow nasal oxygen therapy; Assigned to Arm(s): O2-HNF : high flow nasal oxygen therapy | Intervention Type: DEVICE; Name: O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation; Assigned to Arm(s): O2-HFN/NPPV
C: Arm Label: CF patients HFN; Type: EXPERIMENTAL; Interventions: Device: High flow nasal oxygen cannula | Arm Label: CF patients NIV; Type: EXPERIMENTAL; Interventions: Device: Noninvasive ventilation | Intervention Type: DEVICE; Name: High flow nasal oxygen cannula; Assigned to Arm(s): CF patients HFN | Intervention Type: DEVICE; Name: Noninvasive ventilation; Assigned to Arm(s): CF patients NIV
D: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Brief Summary: Based on prior published pilot studies, the investigators have initiated a larger, multi-site placebo-controlled clinical trial with Alzheimer's disease (AD) patients and individuals diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1) confirming (or denying) the above promising clinical findings, and (2) determining whether or not our formulation can delay MCI "conversion" to AD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3
B: Arm Label: Nutriceutical formulation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutriceutical formulation | Arm Label: Placebo 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutriceutical formulation; Assigned to Arm(s): Nutriceutical formulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 1, Placebo 2
C: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo

Answer: B